Clinical relevance of cytokine-induced changes in drug metabolism

Journal of Pharmacy Practice and Research

Volumn 32, Issue 2, 2002, Pages 147-152

  Davey, Andrew K ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTICOAGULANT AGENT; BETA INTERFERON; CARBAMAZEPINE; CYCLOSPORIN; CYTOCHROME P450; CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEXOBARBITAL; IBUPROFEN; INDINAVIR; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 6; LORAZEPAM; MIDAZOLAM; PHENAZONE; PHENYTOIN; QUININE; THEOPHYLLINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CANCER; DRUG CLEARANCE; DRUG METABOLISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOREGULATION; INFLAMMATION; LIVER CELL; NONHUMAN; REVIEW;

EID: 0036625608     PISSN: 1445937X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jppr2002322147     Document Type: Review

References (68)

1. Remick DG, Friedland JS, editors. Cytokines in Health and Disease. 2nd Ed. New York: Marcel Dekker, Inc.; 1997.
2. Kelso A. Cytokines: Principles and prospects. Immunol Cell Biol 1998; 76: 300-17.
3. Bellomo R. The cytokine network in the critically ill. Anaesth Intensive Care 1992; 20: 288-302.
4. Witkamp R, Monshouwer M. Signal transduction in inflammatory processes, current and future therapeutic targets: A mini review. Vet Q 2000; 22: 11-16.
5. Davey AK, Nicholls PJ. Toxicology of bacterial endotoxins. Toxicology and Ecotoxicology News 1994; 1: 76-80.
6. Barre J, Houin G, Brunner F, Bree F, Tillement JP. Disease-induced modifications of drug pharmacokinetics. Int J Clin Pharmacol Res 1983; 3: 215-26.
7. Whitehouse MW, Beck FJ. Impaired drug metabolism in rats with adjuvant-induced arthritis: A brief review. Drug Metab Dispos 1973; 1: 251-5.
8. Whitehouse MW. Abnormal drug metabolism in rats after an inflammatory insult. Agents & Actions 1973; 3: 312-16.
9. Perrey K, Jonen HG, Kahl GF, Jahnchen E. Elimination and distribution of phenylbutazone in rats during the course of adjuvant-induced arthritis. J Pharmacol Exp Ther 1976; 197: 470-7.
10. Chang KC, Bell TD, Lauer BA, Chai H. Altered theophylline pharrnacokinetics during acute respiratory viral illness. Lancet 1978; 1: 1132-3.
11. Kraemer MJ, Furukawa CT, Koup JR, Shapiro GG, Pierson WE, Bierman CW. Altered theophylline clearance during an influenza B outbreak. Pediatrics 1982; 69: 476-80.
12. Trenholme GM, Williams RL, Rieckmann KH, Frischer H, Carson PE. Quinine disposition during malaria and during induced fever. Clin Pharmacol Ther 1976; 19: 459-67.
13. Griffeth LK, Rosen GM, Tschanz C, Rauckman EJ. Effects of model traumatic injury on hepatic drug metabolism in the rat. I. In vivo antipyrine metabolism. Drug Metab Dispos 1983; 11: 517-25.
14. Griffeth LK, Rosen GM, Rauckman EJ. Effects of model traumatic injury on hepatic drug metabolism in the rat. III. Differential responses of cytochrome P450 subpopulations. Drug Metab Dispos 1984; 12: 588-95.
15. Griffeth LK, Rosen GM, Rauckman EJ. Effects of model traumatic injury on hepatic drug metabolism in the rat. IV. Glucuronidation. Drug Metab Dispos 1985; 13: 391-7.
16. Griffeth LK, Rosen GM, Rauckman EJ. Effects of model traumatic injury on hepatic drug metabolism in the rat. II. In vivo metabolism of hexobarbital and zoxazolamine. Drug Metab Dispos. 1984; 12: 582-7.
17. Griffeth LK, Rosen GM, Rauckman EJ. Effects of model traumatic injury on hepatic drug metabolism in the rat. V. Sulfation and acetylation. Drug Metab Dispos 1985; 13: 398-405.
18. Rauckman EJ, Rosen GM, Post SE, Gillogly SD. Effect of model traumatic injury on hepatic drug-metabolizing enzymes. J Trauma 1980; 20: 884-6.
19. Pessayre D, Allemand H, Benoist C, Afifi F, Francois M, Benhamou JP. Effect of surgery under general anaesthesia on antipyrine clearance. Br J Clin Pharmacol 1978; 6: 505-13.
20. Morgan ET. Regulation of cytochromes P450 during inflammation and infection. Drug Metab Rev 1997; 29: 1129-88.
21. Morgan ET. Regulation of cytochrome p450 by inflammatory mediators: Why and how? [erratum appears in Drug Metab Dispos 2001; 29: 932]. Drug Metab Dispos 2001; 29: 207-12.
22. Renton KW. Hepatic drug metabolism and immunostimulation. Toxicology 2000; 142: 173-8.
23. Abdel-Razzak Z, Loyer P, Fautrel A, Gautier JC, Corcos L, Turlin B, et al. Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture. Mol Pharmacol 1993; 44: 707-15.
24. Gorski JC, Hall SD, Becker P, Affrime MB, Cutler DL, Haehner-Daniels B. In vivo effects of interleukin-10 on human cytochrome P450 activity. Clin Pharmacol Ther 2000; 67: 32-43.
25. Warren GW, Poloyac SM, Gary DS, Mattson MP, Blouin RA. Hepatic cytochrome P-450 expression in tumor necrosis factor-alpha receptor (p55/p75) knockout mice after endotoxin administration. J Pharmacol Exp Ther 1999; 288: 945-50.
26. Siewert E, Bort R, Kluge R, Heinrich PC, Castell J, Jover R. Hepatic cytochrome P450 down-regulation during aseptic inflammation in the mouse is interleukin 6 dependent. Hepatology 2000; 32: 49-55.
27. Bailey DG, Malcolm J, Arnold O, Spence JD. Grapefruit juice-drug interactions. Br J Clin Pharmacol 1998; 46: 101-10.
28. Berg-Candolfi M, Candolfi E, Benet LZ. Suppression of intestinal and hepatic cytochrome P4503A in murine Toxoplasma infection. Effects of N-acetylcysteine and N(G)-monomethyl-L-arginine on the hepatic suppression. Xenobiotica 1996; 26: 381-94.
29. Bertilsson PM, Olsson P, Magnusson KE. Cytokines influence mRNA expression of cytochrome P450 3A4 and MDRI in intestinal cells. J Pharm Sci 2001; 90: 638-46.
30. Kechagias S, Jonsson KA, Borch K, Jones AW. Influence of age, sex, and Helicobacter pylori infection before and after eradication on gastric alcohol dehydrogenase activity. Alcohol Clin Exp Res 2001; 25: 508-12.
31. Nicholson TE, Renton KW. Modulation of cytochrome P450 by inflammation in astrocytes. Brain Res 1999; 827: 12-18.
32. Monshouwer M, Witkamp RF, Nujmeijer SM, Van Amsterdam JG, Van Miert AS. Suppression of cytochrome P450- and UDP glucuronosyl transferase-dependent enzyme activities by proinflammatory cytokines and possible role of nitric oxide in primary cultures of pig hepatocytes. Toxicol Appl Pharmacol 1996; 137: 237-44.
33. Adachi Y, Yokoyama Y, Nanno T, Yamamoto T. Potentiation of warfarin by interferon. BMJ 1995; 311: 292.
34. Serratrice J, Durand JM, Morange S. Interferon-alpha 2b interaction with acenocoumarol. Am J Hematol 1998; 57: 89.
35. Okuno H, Takasu M, Kano H, Seki T, Shiozaki Y, Inoue K. Depression of drug-metabolizing activity in the human liver by interferon-beta. Hepatology 1993; 17: 65-9.
36. Israel BC, Blouin RA, McIntyre W, Shedlofsky SI. Effects of interferon-alpha monotherapy on hepatic drug metabolism in cancer patients. Br J Clin Pharmacol 1993; 36: 229-35.
37. Jonkman JH, Nicholson KG, Farrow PR, Eckert M, Grasmeijer G, Oosterhuis B, et al. Effects of alpha-interferon on theophylline pharmacokinetics and metabolism. Br J Clin Pharmcol 1989; 27: 795-802.
38. Skowron G, Stein D, Drusano G, Melbourne K, Bilello J, Mikolich D, et al. The safety and efficacy of granulocyte-macrophage colony- stimulating factor (Sargramostim) added to indinavir- or ritonavir-based antiretroviral therapy: A randomized double-blind, placebo-controlled trial. J Infect Dis 1999; 180: 1064-71.
39. Piscitelli SC, Vogel S, Figg WD, Raje S, Forrest A, Metcalf JA, et al. Alteration in indinavir clearance during interleukin-2 infusions in patients infected with the human immunodeficiency virus. Pharmacotherapy 1998; 18: 1212-16.
40. Chabot GG, Flaherty LE, Valdivieso M, Baker LH. Alteration of dacarbazine pharmacokinetics after interleukin-2 administration in melanoma patients. Cancer Chemother Pharmacol 1990; 27: 157-60.
41. Krown SE, Gold JW, Niedzwiecki D, Bundow D, Flomenberg N, Gansbacher B, et al. Interferon-alpha with zidovudine: Safety, tolerance, and clinical and virologic effects in patients with Kaposi sarcoma associated with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1990; 112: 812-21.
42. Kovacs JA, Deyton L, Davey R, Falloon J, Zunich K, Lee D, et al. Combined zidovudine and interferon-alpha therapy in patients with Kaposi sarcoma and the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1989; 111: 280-7.
43. Nokta M, Loh JP, Douidar SM, Ahmed AE, Pollard RB. Metabolic interaction of recombinant interferon-beta and zidovudine in AIDS patients. Journal of Interferon Research 1991; 11: 159-64.
44. Burger DM, Meenhorst PL, Koks CHW, Beijnen JH. Drug interactions with zidovudine. AIDS 1993; 7: 445-60.
45. Piscitelli SC, Amatea MA, Vogel S, Bechtel C, Metcalf JA, Kovacs JA. Effects of cytokines on antiviral pharmacokinetics: An alternative approach to assessment of drug interactions using bioequivalence guidelines. Antimicrob Agents Chemother 1996; 40: 161-5.
46. Dinant HJ, Dijkmans BA. New therapeutic targets for rheumatoid arthritis. Pharm World Sci 1999; 21: 49-59.
47. Narula SK, Coffman R, editors. New Cytokines as Potential Drugs. Basel: Birkhauser Verlag; 2000.
48. Boucher BA, Hanes SD. Pharmacokinetic alterations after severe head injury. Clinical relevance. Clin Pharmacokinet 1998; 35: 209-21.
49. Austin KL, Stapleton JV, Mather LE. Pethidine clearance during continuous intravenous infusions in postoperative patients. Br J Clin Pharmacol 1981; 11: 25-30.
50. Bonate PL. Pathophysiology and pharmacokinetics following burn injury. Clin Pharmacokinet 1990; 18: 118-30.
51. Blumenkopf B, Lockhart WS Jr. Herpes zoster infection and use of oral anticoagulants. A potentially dangerous association. JAMA 1983; 250: 936-7.
52. Lee BL, Wong D, Benowitz NL, Sullam PM. Altered patterns of drug metabolism in patients with acquired immunodeficiency syndrome. Clin Pharmacol Ther 1993; 53: 529-35.
53. Soons PA, Grib C, Breimer DD, Kirch W. Effects of acute febrile infectious diseases on the oral pharmacokinetics and effects of nitrendipine enantiomers and of bisoprolol. Clin Pharmacokinet 1992; 23: 238-48.
54. Kairaluoma MI, Sotaniemi EA, Mokka RE, Nuutinen L, Karkola P, Larmi TK. Liver drug metabolism in patients undergoing open-heart surgery. Scand J Thorac Cardiovasc Surg 1979; 13: 281-5.
55. McKindley DS, Hanes S, Boucher BA. Hepatic drug metabolism in critical illness. Pharmacotherapy 1998; 18: 759-78.
56. Christie J, Markowsky SJ, Valdes C. Acute trauma alters morphine clearance. J Trauma 1995; 39: 749-52.
57. Renton KW, Gray JD, Hall RI. Decreased elimination of theophylline after influenza vaccination. Can Med Assoc J 1980; 123: 288-90.
58. Jamali F, Kunz-Dober CM. Pain-mediated altered absorption and metabolism of ibuprofen: An explanation for decreased serum enantiomer concentration after dental surgery. Br J Clin Pharmacol 1999; 47: 391-6.
59. Chen YL, Le Vraux V, Leneveu A, Dreyfus F, Stheneur A, Florentin I, et al. Acute-phase response, interleukin-6, and alteration of cyclosporine pharmacokinetics. Clin Pharmacol Ther 1994; 55: 649-60.
60. Hirooka K, Shimizu M, Mineshita S. Theophylline metabolism after cardiac surgery. J Clin Pharmacol 2001; 41: 157-62.
61. Gidal BE, Reiss WG, Liao JS, Pitterle ME. Changes in interleukin-6 concentrations following epilepsy surgery: Potential influence on carbamazepine pharmacokinetics. Ann Pharmacother 1996; 30: 545-6.
62. Shedlofsky SI, Israel BC, Tosheva R, Blouin RA. Endotoxin depresses hepatic cytochrome P450-mediated drug metabolism in women. Br J Clin Pharmacol 1997; 43: 627-32.
63. Shedlofsky SI, Israel BC, McClain CJ, Hill DB, Blouin RA. Endotoxin administration to humans inhibits hepatic cytochrome P450-mediated drug metabolism. J Clin Invest 1994; 94: 2209-14.
64. McKindley DS, Boucher BA, Hess MM, Rodman JH, Feler C, Fabian TC. Effect of acute phase response on phenytoin metabolism in neurotrauma patients. J Clin Pharmacol 1997; 37: 129-39.
65. Burckart GJ, Frye RF, Kelly P, Branch RA, Jain A, Fung JJ, et al. Induction of CYP2E1 activity in liver transplant patients as measured by chlorzoxazone 6-hydroxylation. Clin Pharmacol Ther 1998; 63: 296-302.
66. Verde CR, Simpson MI, Frigoli A, Landoni MF. Enantiospecific pharmacokinetics of ketoprofen in plasma and synovial fluid of horses with acute synovitis. J Vet Pharmacol Ther 2001; 24: 179-85.
67. Neuman MG, Cameron RG, Haber JA, Katz GG, Malkiewicz IM, Shear NH, Inducers of cytochrome P450 2El enhance methotrexate-induced hepatocytoxicity. Clin Biochem 1999; 32: 519-36.
68. Park GR. Pharmacokinetics and pharmacodynamics in the critically ill patient. Xenobiotica 1993; 23: 1195-230.